{Reference Type}: Journal Article
{Title}: Neurobehavioral Outcomes of Children with Antenatal Exposure to Antiseizure Medications.
{Author}: Bhaskaran D;Thomas S;Scaria LM;
{Journal}: Indian J Pediatr
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 8
{Factor}: 5.319
{DOI}: 10.1007/s12098-024-05165-3
{Abstract}: <B>OBJECTIVE: </B>To evaluate the effect of antiepileptic medications prescribed to mothers during pregnancy on the development and behavior of children.<BR><B>METHODS: </B>From the Kerala Registry of Epilepsy and Pregnancy, 98 children between the ages of 1½ to 2½ y were consecutively chosen. Children of mothers who did not have epilepsy during pregnancy and not exposed to antiseizure medications (ASMs) antenatally were selected as comparator group. Developmental assessment of the children was performed using Developmental Assessment Scale for Indian Infants (DASII) and Receptive-Expressive Emergent Language Scale (REELS). Behavior outcomes were assessed using Child Behavior Checklist.<BR><B>RESULTS: </B>A significant delay in expressive language skills was seen in children exposed to antiseizure medication with an odds ratio of 2.539 (95% CI 1.10, 5.85, P = 0.026). A delay in expressive language skills was seen in polytherapy with clobazam (odds ratio 6.83; 95% CI 2.17, 21.56, P < 0.001). Also, delay was seen in receptive language skills in the same polytherapy group (odds ratio of 7.333; 95% CI 2.16, 24.92, P < 0.001). There were no statistically significant differences between study and comparative groups in motor and mental quotient domains and behavioral outcomes.<BR><B>CONCLUSIONS: </B>The finding of speech delay in children exposed to ASMs is significant since individuals with a history of childhood speech or language disorders may experience long-term difficulties in mental health, social well-being, and academic outcomes.